Navigation Links
ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery

Cleveland, OH (PRWEB) April 09, 2013

Partnerships between industry and vendors are a positive trend for the drug discovery industry when the right companies come together, as they allow for innovation and also optimize the process to facilitate identifying the right drugs faster and more effectively. On Friday, May 10th, 2013, ChanTest will host its second User Meeting: Partnerships in Drug Discovery. The User Meeting will be held in South San Francisco, California at the Westin San Francisco Airport, 1 Old Bayshore Highway, Millbrae, CA 94030.

This complimentary event highlights the latest advances and strategies for Ion channel and GPCR screening, along with profiling for drug discovery and preclinical cardiac safety testing. “The second ChanTest User Meeting: Partnerships in Drug Discovery will bring together users and partners, present new offerings, project news and coordinate future developments,” said Chris Mathes, Ph.D., Chief Commercial Officer.

Click here to register.

This year’s keynote speaker will be Dr. Philip Sager, Chair of the Scientific Committee, Cardiac Safety Research Consortium. He will speak on “Preclinical and Clinical Development”. The event is co-sponsored by Axion Biosystems, Cellular Dynamics International, ACEA Biosciences, Sophion and Molecular Devices.

Friday, May 10, 2013
2nd ChanTest User Meeting: Partnerships in Drug Discovery
Westin San Francisco Airport
1 Old Bayshore Highway
Millbrae, CA 94030



14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.

Visit to learn more about what we do.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
3. Probiotic Action Announces New Edible Probiotic Trend
4. Core and More Technologies Announces the Most Comprehensive and Cost-effective Paid Search Advertising Packages Available in the Industry Today
5. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
6. Probiotic Action Announces New Use for Their Adult Acne Treatment and Explains its Beauty Benefits for Women
7. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
8. ACC Clean Energy Challenge Announces Elite Eight Plus Two, Will Vie to Reach Final Four
9. Seahorse Bioscience Announces AACR Travel Award Recipients
10. Bio-IT World Announces Best of Show Awards Finalists for the Bio-IT World Conference & Expo
11. LamdaGen Corporation Announces Japan Patent Issuance for Enzymatic Diagnostic Assays on Plasmonic Nano-Sensors
Post Your Comments:
(Date:10/12/2015)... ROSEVILLE, Minn. , Oct. 12, 2015 /PRNewswire/ ... Drug Administration (FDA) has designated its lead Microbiota ... for the treatment of recurrent Clostridium difficile ... gastrointestinal (GI) infection that causes 29,000 deaths in ... clinical stage biotechnology company that was founded to ...
(Date:10/12/2015)... , 12 de octubre de 2015 El ... llegó a un récord en el congreso con su ... de la International Plasma Awareness Week (IPAW), que se ... está patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 2015 offers ... enriched online experience --> ... version for enriched online experience --> ... alternative to print version for enriched online experience ... technical and medical information products and services, announced today ...
Breaking Biology Technology:
(Date:10/12/2015)... India , October 12, 2015 ... a new market research report on the "Digital Security ... technology, & Security Token), by Software (Anti-Phishing, Authentication, Network ... to 2020", published by MarketsandMarkets, the market is expected ... to 2020, and reach USD 14.6 Billion by 2020. ...
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/7/2015)... October 7, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Washington , former long- term executive at American Express ... --> NXTD ) ("NXT-ID" or the "Company"), a ... market and creator of the Wocket® smart wallet announces ...
Breaking Biology News(10 mins):